Skip to main content

Advertisement

Figure 1 | Arthritis Research & Therapy

Figure 1

From: Role of RANKL inhibition in osteoporosis

Figure 1

Changes in bone mineral density with denosumab, alendronate, and placebo. Shown here are mean percentage changes from baseline at 12 months in bone mineral density at the lumbar spine, total hip region, and distal third of the radius in women who received placebo (open bars), denosumab 60 mg every 6 months (solid bars), and alendronate 70 mg once weekly (stippled bars) [46]. *P < 0.001 versus placebo; **P < 0.05 versus placebo; nominal P < 0.01 versus alendronate. SE, standard error.

Back to article page